Nephrotic syndrome with acute kidney injury due to focal segmental glomerulosclerosis following long-term treatment with minodronate.
Acute kidney injury
Bisphosphonates
Focal segmental glomerulosclerosis
Minodronate
Nephrotic syndrome
Journal
CEN case reports
ISSN: 2192-4449
Titre abrégé: CEN Case Rep
Pays: Japan
ID NLM: 101636244
Informations de publication
Date de publication:
02 2022
02 2022
Historique:
received:
26
04
2021
accepted:
16
08
2021
pubmed:
30
8
2021
medline:
22
4
2022
entrez:
29
8
2021
Statut:
ppublish
Résumé
Although bisphosphonates are well known to cause kidney disease, there are very few published cases of focal segmental glomerulosclerosis (FSGS) following treatment with minodronate. Here we report the case of an 86-year-old woman who developed acute kidney injury and nephrotic syndrome after receiving monthly oral minodronate for 24 months. Kidney biopsy revealed cellular variant FSGS. Treatment was initiated with the discontinuation of minodronate followed by intravenous methylprednisolone pulse and prednisolone at 35 mg/day. Subsequently, the patient's renal function gradually worsened, requiring initiation of hemodialysis. However, renal function and proteinuria improved markedly and hemodialysis was withdrawn 1 month after the initiation of steroid therapy. This is, to our knowledge, the first published case of FSGS induced by long-term use of minodronate, and also the first case of cellular variant FSGS induced by bisphosphonates although collapsing variant of FSGS is commonly caused by bisphosphonates. Our study indicates that patients on bisphosphonates should be closely monitored for proteinuria and renal impairment, regardless of the type of bisphosphonate.
Identifiants
pubmed: 34455572
doi: 10.1007/s13730-021-00637-3
pii: 10.1007/s13730-021-00637-3
pmc: PMC8811011
doi:
Substances chimiques
Diphosphonates
0
Imidazoles
0
YM 529
127657-42-5
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
120-125Informations de copyright
© 2021. Japanese Society of Nephrology.
Références
Ohishi T, Matsuyama Y. Minodronate for the treatment of osteoporosis. Ther Clin Risk Manag. 2018;14:729–39.
doi: 10.2147/TCRM.S149236
Markowitz GS, Appel GB, Fine PL, Fenves AZ, Loon NR, Jagannath S, Kuhn JA, Dratch AD, D’Agati VD. Collapsing focal segmental glomerulosclerosis following treatment with high-dose pamidronate. J Am Soc Nephrol. 2001;12:1164–72.
doi: 10.1681/ASN.V1261164
Barri YM, Munshi NC, Sukumalchantra S, Abulezz SR, Bonsib SM, Wallach J, Walker PD. Podocyte injury associated glomerulopathies induced by pamidronate. Kidney Int. 2004;65:634–41.
doi: 10.1111/j.1523-1755.2004.00426.x
Desikan R, Veksler Y, Raza S, Stokes B, Sabir T, Li ZJ, Jagannath S. Nephrotic proteinuria associated with high-dose pamidronate in multiple myeloma. Br J Haematol. 2002;119:496–9.
doi: 10.1046/j.1365-2141.2002.03826.x
Bodmer M, Amico P, Mihatsch MJ, Haschke M, Kummer O, Krähenbühl S, Mayr M. Focal segmental glomerulosclerosis associated with long-term treatment with zoledronate in a myeloma patient. Nephrol Dial Transplant. 2007;22:2366–70.
doi: 10.1093/ndt/gfm209
Neyra JA, Vaidya OU, Hendricks A, Sambandam KK. Collapsing focal segmental glomerulosclerosis resulting from a single dose of zoledronate. Nephron Extra. 2014;4:168–74.
doi: 10.1159/000366450
Miura N, Mizuno N, Aoyama R, Kitagawa W, Yamada H, Nishikawa K, Imai H. Massive proteinuria and acute renal failure after oral bisphosphonate (alendronate) administration in a patient with focal segmental glomerulosclerosis. Clin Exp Nephrol. 2009;13:85–8.
doi: 10.1007/s10157-008-0078-x
Prikis M, Gibson PC, Weise WJ. Alendronate-associated focal segmental glomerulosclerosis. NDT Plus. 2009;2:91–2.
pubmed: 25949300
Jia N, Cormack FC, Xie B, Shiue Z, Najafian B, Gralow JR. Collapsing focal segmental glomerulosclerosis following long-term treatment with oral ibandronate: case report and review of literature. BMC Cancer. 2015;15:535.
doi: 10.1186/s12885-015-1536-y
Komada T, Morishita Y, Kitamura M, Iwazu K, Numata A, Kobayashi T, Yamamoto H, Akimoto T, Saito O, Ando Y, Takemoto F, Muto S, Yumura W, Kusano E. Acute kidney injury in a patient with nephrotic syndrome due to focal segmental glomerular nephritis induced by a single oral administration of high-dose bisphosphonate (minodronate). Intern Med. 2013;52:1383–7.
doi: 10.2169/internalmedicine.52.0094
Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney Int. 2008;74:1385–93.
doi: 10.1038/ki.2008.356
Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res. 2006;12:6222s-s6230.
doi: 10.1158/1078-0432.CCR-06-0843
Rogers MJ, Gordon S, Benford HL, Coxon FP, Luckman SP, Monkkonen J, Frith JC. Cellular and molecular mechanisms of action of bisphosphonates. Cancer. 2000;88:2961–78.
doi: 10.1002/1097-0142(20000615)88:12+<2961::AID-CNCR12>3.0.CO;2-L
Miller PD. The kidney and bisphosphonates. Bone. 2011;49:77–81.
doi: 10.1016/j.bone.2010.12.024
Dunford JE, Thompson K, Coxon FP, Luckman SP, Hahn FM, Poulter CD, Ebetino FH, Rogers MJ. Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonate. J Pharmacol Exp Ther. 2001;296:235–42.
pubmed: 11160603
Stokes MB, Valeri AM, Markowitz GS, D’Agati VD. Cellular focal segmental glomerulosclerosis: clinical and pathologic features. Kidney Int. 2006;70:1783–92.
doi: 10.1038/sj.ki.5001903
Chun MJ, Korbet SM, Schwartz MM, Lewis EJ. Focal segmental glomerulosclerosis in nephrotic adults: presentation, prognosis, and response to therapy of the histologic variants [presentation]. J Am Soc Nephrol. 2004;15:2169–77.
doi: 10.1097/01.ASN.0000135051.62500.97
Schwartz MM, Korbet SM, Rydell J, Borok R, Genchi R. Primary focal segmental glomerular sclerosis in adults: prognostic value of histologic variants. Am J Kidney Dis. 1995;25:845–52.
doi: 10.1016/0272-6386(95)90566-9